The U.S. Food and Drug Administration (FDA) has added new restrictions on how rosiglitazone-containing medicines (Avandia, Avandamet, Avandaryl): Healthcare providers must enroll in a special program in order to prescribe the medicines, and patients must enroll in the same program in order to obtain their medicines through the mail. After November 18, 2011, rosiglitazone-containing medicines will no longer be available through retail pharmacies. Read more.
FDA restricts patient access to rosiglitazone
The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
